Please use this identifier to cite or link to this item:
標題: Thiabendazole對雌二醇誘發大鼠乳腺腫瘤之影響
Effect of thiabendazole on 17β-estradiol-induced mammary tumor in rats
作者: 袁朝云
Yuan, Chao-Yun
關鍵字: 乳腺腫瘤;17β-estradiol;腦下垂體;環化酶;thiabendazole;mammary tumor;pituitary gland;aromatase
出版社: 生命科學院碩士在職專班
引用: 1.Russo J, Hu YF, Yang X, Russo IH. Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer. National Cancer Institute Monographs, 2000. 27: p. 17-37. 2.Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Research, 2002. 4: p. 197-201. 3.Henderson BE, Feigelson HS. Hormone carcinogenesis. Carcinogenesis, 2000. 21(3): p. 427-433. 4.Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas, 2001. 38: p. 103-116. 5.Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha- negative human breast cancer. Breast Cancer Research, 2004. 6(6): p. 240-245. 6.Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. PNAS, 2008. 105: p. 3527-3532. 7.Mahavni V, MD, Sood AK, MD. Hormone replacement therapy and cancer risk. Current Opinion in Oncology, 2001. 13: p. 384-389. 8.Rossouw JE, Aanderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: principal results From the Women''s Health Initiative randomized controlled trial. Journal of the American Medical Association, 2002. 288(3): p. 321- 333. 9.Venkitaraman AR, Cancer Susceptibility and the Functions of BRCA1 and BRCA2. Cell, 2002. 108: p. 171-182. 10.King MC, Marks JH, Mandell JB. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science, 2003. 302: p. 643-646. 11.Walsh T, King MC. Ten Genes for Inherited Breast Cancer. Cancer Cell, 2007. 11: p. 103-105. 12.Mincey BA. Genetics and the Management of Women at High Risk for Breast Cancer. The Oncologist, 2003. 8: p. 466- 473. 13.Rudel RA, Fenton SE, Ackerman JM, Euling SY, Makris SL. Environmental Exposures and Mammary Gland Development: State of the Science, Public Health Implications, and Research Recommendations. Environmental Health Perspectives, 2011. 119(8): p. 1053-1061. 14.Fenton, S.E. Endocrine-Disrupting Compounds and Mammary Gland Development: Early Exposure and Later Life Consequences. Endocrinology, 2006. 147(6): p. 18-24. 15.Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 2004. 4: p. 253- 265. 16.LaPensee EW, Jonathan NB. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocrine-Related Cancer, 2010. 17: p. 91-107. 17.Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology, 2006. 147: p. 269-276. 18.Li SA, Weroha SJ, Tawfik O, Li JJ. Prevention of solely estrogen-induced mammary tumors in female ACI rats by tamoxifen: evidence for estrogen receptor mediation. Society for Endocrinology, 2002. 175: p. 297-305. 19.Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second- line treatment of postmenopausal women with advanced breast cancer. Cancer Treatment Reviews, 2005. 31: p. 274-282. 20.Abdulkareem IH, Zurmi IB. Review of hormone treatment of breast cancer. Nigerian Journal of Clinical Practice, March 2012. 15(1): p. 9-14. 21.Nelson LR, Bulun SE. Estrogen production and action. Journal of the American Academy of Dermatology, 2001. 45 (3): p. 116-124. 22.Ryan KJ. Biochemistry of Aromatase: Significance to Female Reproductive Physiology. Cancer Research, 1982. 42: p. 3343-3344. 23.Spelsberg TC, Rejman RJJ, Goldberger RA, et al. Steroid Action on Gene Expression: Possible Roles of Regulatory Genes and Nuclear Acceptor Sites. Biology of Reproduction, 1989. 40: p. 54-69. 24.Tsuchiya Y, Nakajima M, Yokoi T, Cytochrome P450- mediated metabolism of estrogens and its regulation in human. Cancer Letters, October 2004. 227: p. 115-124. 25.Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci, 1997. 94: p. 10937-10942. 26.Yager JD, Davidson NE. Estrogen Carcinogenesis in Breast Cancer. The New England Journal of Medicine, 2006. 354: p. 270-282. 27.Turan VK, Sanchez RI, Li JJ, et al. The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4- hydroxyestradiol, 16alpha-hydroxyestradiol, and 4- hydroxyestrone. Journal of Endocrinology, 2004. 183: p. 91-99. 28.Levin ER. Integration of the Extranuclear and Nuclear Actions of Estrogen. Mol Endocrinol, 2005. 19(8): p. 1951-1959. 29.Kuiper GGJM, Enmarl E, Pelto-Huikko M, Nilsson S, Gustafsson J, Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA, 1996. 93 (12): p. 5925-5930. 30.Herynk MH, Fuqua SAW. Estrogen Receptor Mutations in Human Disease. Endocrine Reviews, 2004. 25(6): p. 869- 898. 31.Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Letters, 1996. 392(1): p. 49-53. 32.Metzger D, Ali S, Bornert JM, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. The Journal of Biological Chemistry, 1995. 270(16): p. 9535-9542. 33.Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell, 1987. 51(6): p. 941-951. 34.Enmark E, Pelto-Huikko M., Grandien K, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. Journal of Clinical Endocrinology and Metabolism, 1997. 82(12): p. 4258-4265. 35.Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β. Endocrinology, 1997. 138(3): p. 863-870. 36.Speirs V, Skliris GP, Burdall SE, Carder PJ, Distinct expression patterns of ERα and ERβ in normal human mammary gland. J Clin Pathol, 2002. 55: p. 371-374. 37.Russo IH, Russo J. Mammary Gland Neoplasia in Long-Term Rodent Studies. Environmental Health Perspectives, 1996. 104: p. 938-967. 38.Cardiff RD, Wellings SR. The Comparative Pathology of Human and Mouse Mammary Glands. Journal of Mammary Gland Biology and Neoplasia, 1999. 4: p. 105-122. 39.Wagner KU. Models of breast cancer: quo vadis, animal modeling? Breast Cancer Research, 2003. 6(1): p. 31-38. 40.Matulka LA, Wagner KU. Models of breast cancer. Cancer, 2005. 2(1): p. 1-6. 41.Dunning WF., Curtis MR, Segaloff A. Strain differences in response to estrone and the induction of mammary gland, adrenal, and bladder cancer in rats. Cancer Research, 1953. 13: p. 147-152. 42.Shull JD, Spady TJ, Snyder MC, Johansson SL , Pennington KL. Ovary-intact, but not ovariectomized female ACI rats treated with 17b-estradiol rapidly develop mammary carcinoma. Carcinogenesis, 1997. 18(8): p. 1595-1601. 43.Lloyd RV. Estrogen-Induced Hyperplasia and Neoplasia in the Rat Anterior Pituitary Gland. Am J Pathol, 1983. 113 (2): p. 198-206. 44.Ravoori S, Vadhanam MV, Sahoo S, Srinivasan C, Gupta RC. Mammary tumor induction in ACI rats exposed to low levels of 17s-estradiol. International Journal of Oncology, 2007. 31: p. 113-120. 45.Moraes DCD, Vaisman M, Conceic﹐a˜o FL, Ortiga-Carvalho TM, Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors. Journal of Endocrinology, 2012. 215: p. 239-245. 46.Nishino K, Niwa Y, Mizutani T, et al. Carcinoma Indirectly Caused by Pituitary Prolactinoma: A Case Report. Case Reports in Oncology, 2013. 6: p. 25-30. 47.Upadhyay MP, West EP, Sharma AP. Keratitis due to Aspergillus flavus successfully treated with thiabendazole. British Journal of Ophthalmology, 1980. 64: p. 30-32. 48.Portugal R, Schaffel R, Almeida L, Spector N, Nucci M. Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematologic diseases: a randomized, double-blind placebo-controlled study. Haematologica 2002. 87(6): p. 633-634. 49.Rafael IA, Oltra-Alcaraz C, Soler-Company E, Sanchez- Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother, 2004. 5(12): p. 2615-2619. 50.Devereux M, Mccann M, Shea DO, et al. Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(4-thiazolyl)benzimidazole {thiabendazole}: X-ray crystal structures of [Cu(TBZH) 2Cl]Cl.H2O. EtOH and TBZH2NO3 (TBZH=thiabendazole). Inorganic Biochemistry, March 2004. 98: p. 1023-1031. 51.Reregistration Eligibility Decision (RED) Thiabendazole, E.P. Agency, Editor. 2002: USA. 52.Groten JP, Butler W, Feron VJ, Kozianowski G, Renwick AG, Walker R. An Analysis of the Possibility for Health Implications of Joint Actions and Interactions between Food Additives. Regulatory Toxicology and Pharmacology, 2000. 31: p. 77-91. 53.Ayub M, Levell MJ. The inhibition of human prostatic aromatase activity by imidazole drugs including ketoconazole and 4-hydroxyandrostenedione. Biochem Pharmacol, 1990. 40(7): p. 1569-1575. 54.Sanderson JT. The Steroid Hormone Biosynthesis Pathway as a Target for Endocrine-Disrupting Chemicals. Toxicological Sciences, June 27, 2006. 94(1): p. 3-21. 55.Ginsburg E, Vonderhaar BK. Prolactin Synthesis and Secretion by Human Breast Cancer Cells. Cancer Research, 1995. 55: p. 2591-2595. 56.Ayub M, Levell MJ. Structure-activity relationships of the inhibition of human placental aromatase by imidazole drugs including ketoconazole. Journal of Steroid Biochemistry, 1988. 31: p. 65-72. 57.Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocrine- Related Cancer, 2003. 10: p. 193-202. 58.Palmieri C, Lam EWF, Mansi J, et al. The Expression of ER βcx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival. Clinical Cancer Research, 2004. 10: p. 2421-2428. 59.Mense SM, Remotti F, Bhan A, et al. Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicology and Applied Pharmacology, 2008. 232: p. 78-85. 60.Leung CKH, Shiu RPC. Required Presence of Both Estrogen and Pituitary Factors for the Growth of Human Breast Cancer Cells in Athymic Nude Mice. Cancer Research, 1981. 41: p. 546-551. 61.Rasmussen LM, Frederiksen KS, Din N, et al. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocrine- Related Cancer, 2010. 17: p. 809-822.
現代文明病倍增,癌症更是現代人最大隱憂,惡性腫瘤已躍居十大死因之首,乳癌為女性最主要癌症之一,發生率第一位,死亡率第四位,由於飲食西化及生活型態改變影響下,乳癌發生率年年增高,因此預防與治療乳癌乃新藥重要挑戰。本實驗室先前研究顯示,染劑Rhodamine B口服投予懷孕大鼠第0-20天時誘發胚胎早死亡現象,而該染劑具促進環化酶(Aromatase )作用,因此增加睪固酮(testosterone)轉化為雌二醇濃度,因此本實驗室接著再設計共同以Rhodamine B與咪唑類藥物Thiabendazole(TBZ)口服處理懷孕大鼠第0-20天,目的在以具環化酶拮抗作用之TBZ緩解Rhodamine B對大鼠胚胎早死亡之影響。結果顯示,TBZ可緩解胚胎死亡影響。
基於此一原則,本研究目的在探討TBZ是否可以拮抗以雌二醇誘發大鼠乳腺腫瘤。實驗設計為以雌二醇5、10及15 mg/pellet/rat個別混合處理TBZ 50、100及200 mg/pellet/rat。處理動物為10週齡Wistar品系雌大鼠。處理方法為埋植錠劑於大鼠背頸部皮下,觀察期間10個月。結果顯示,大部分大鼠體重隨處理埋植時間增加而增加,肉眼與病理組織判斷腫瘤發生率,雌二醇處理組隨劑量增加而增加,但最高劑量與中劑量相同。TBZ則未誘發乳腺腫瘤,混合處理雌二醇5 mg/pellet/rat與TBZ 50、100及200 mg/pellet/rat未緩解乳腺腫瘤,但混合處理雌二醇10或15 mg/pellet/rat個別與TBZ 50、100及200 mg/pellet/rat,儘管統計上不顯著但有減少乳腺腫瘤現象。免疫染色結果顯示,乳腺腫瘤與動情素受體(ERα、ERβ)

The diseases are increasing with industrialization especially in cancer, which is one of top ten. Breast cancer is one of the most serious diseases with number one in incidence and number four in death rate. Due to the westernized food and change of live style the incidence of breast cancer is increasing with year. It is quite important for us to develop new drugs for breast cancer. Our previous study showed that pregnant rat was orally administered in utero exposure with stain Rhodamine B resulted in severe embryo lethality. Previous report showed that Rhodamine B increased the aromatase activity, which transfer testosterone into estradiol. Based on the aromatase antagonistic activity by thiabendazole our laboratory conduct a study to investigate the effect of co-treatment with thiabendazole and Rhodamine B on embryo lethality in rats. Results showed that thiabendazole completely relieved the embryo lethality in rats.
Based on the hypothesis this study aim to investigate if the thiabendazole antagonize the estradiol-induced mammary tumors in rats. Wistar rats were implanted with 5, 10 and 15 mg 17β-estradiol/pellet/rat, 50, 100 and 200 mg/pellet/rat thiabendazole, 5, 10 and 15 mg 17β-estradiol/pellet/rat each and 50, 100 and 200 mg/pellet/rat thiabendazole. Wistar rats, 10 week old, were implanted for 10 months. Results showed that body weight were increased with treatment period. The incidence of breast tumor with gross and pathology were as follows. Positive control 17β-estradiol induced breast tumor with dose response while thiabendazole did not. Though the result is not statistically significant, co-treatment with 10 and 15 mg 17β-estradiol/pellet/rat and 50, 100 and 200 mg/pellet/rat thiabendazole decreased the incidence of breast cancer when compared with 17β-estradiol alone. Immunohistochemistry data showed that 17β-estradiol induced ERα activity but not in ERβ and aromatase. Co-treatment with 17β-estradiol each and various thiabendazole significantly decreased the ERα activity with dose response.
We concluded that the thiabendazole antagonistic effect on the 17β-estradiol induced breast cancer and the result is near the significant level statistically. Owing to the unclear underlying mechanism of breast cancer and the role of aromatase in caner induction it is need to be done for the prevention.
其他識別: U0005-2608201309381400
Appears in Collections:生命科學院

Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.